definiens: inthecaseofncn•cashsales, shalllmeanthefåirmarketvalueofallequivalent orotherconsideration receivedbyOPEXAfortheLicensedPatentPendingProductsorLicensedPatentedProducts1.10 meananymodifications, variationsandimprovements tothefollowingaspectsOftheTechnology;(ii)Materialsandprocedures forAutologous T•cellvaccination forMultipleSclerosisandotherautoimmune disorders;T - cellreceptorsequences andtherapeutic - diagnostic productsderivedfromthemthatdirectT•cellantigenrecognition specificity inMultipleSclerosis andotherautoimmune disorders;2https://www.sec.gov / Archives / edgar / data/1069308/000165495416001412 / opxa_ex 101.htm 2/24Searchable PDF created by OCR.space ( Free Version)3/2/22, 1 1:41 AM Untitled Documenthttps://www .sec.gov / Archives / edgar / data/1069308/000165495416001412 / opxa_ex101.htm 3/24 3/2/22,11:41AM(iii)(iv)Untitled DocumentCombinations Ofpregnancy - related hormones thatsuppressautoreactive T•cellmigration, proliferation oractivityagainstautoantigens inMultipleSclerosisorotherautoimmune disorders ; andMaterialsandprocedures fordevelopment ofavaccineagainsthumanherpesvirus•6;whetherpatentable ornot, thatduringthetwoyearsbetweentheAgreement Dateandthesecondanniversary OftheAgreement Date, are(i)conceived orreducedtopractice;(ii)areownedbyBAYLORorbecomepropertyOfBAYLORand(iii)ariseoutOfworkperformedinlaboratoryatBAYLORthatisunderthedirectsupervision oftheDevelopers,1.11isasdefinedinParagraph 5.4